Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 94

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 94
---
 any competitive advantage;                                                                      |

| • |     | our competitors, many of whom have substantially greater resources than we do and many of whom have made                                                                                            
 significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; |

| • |     | there may be significant pressure on the U.S. government and international governmental bodies to limit the scope                                                              
 of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; |

| • |     | countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. 
 courts, allowing foreign competitors a better opportunity to create, develop and market competing products;       |

| • |     | other parties may have designed around our claims or developed technologies that may be related or competitive to                                                                                                                                        
 our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same methods or devices or by claiming subject matter that could 
 dominate our patent position;                                                                                                                                                                                                                            |

57

| • |     | any successful intellectual property challenge to any patents owned by or licensed to us could deprive us of                                         
 rights necessary for the practice of our technologies or the successful commercialization of any products or product candidates that we may develop; |

| • |     | because patent applications in the United States and most other countries are confidential for a period of time                                                                           
 after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our product candidates, proprietary technologies and their uses; and |

The patent prosecution process is also expensive and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. If the patent applications we hold or in-licensewith respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for ZTlido, GLOPERBA, ELYXYB and our product candidates, it could dissuade other companies from collaborating with us